Pancreatic cancer stemness: dynamic status in malignant progression

Zhao, Yutong; Qin, Cheng; Zhao, Bangbo; Wang, Yuanyang; Li, Zeru; Li, Tianyu; Yang, Xiaoying; Wang, Weibin

doi:10.1186/s13046-023-02693-2

Cited by 9 publications

(9 citation statements)

References 189 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So, identifying markers-specific signaling pathways would be helpful. 213 Mutations in CDKN2A, SMAD4, TP53, and KRAS are linked to advanced PC stages and can be utilized as markers for prognosis. 131 However, they are not specific to PC as they could be found in non-small cell lung cancer and in colorectal cancer.…”

Section: Role Of Exosomes In Tumor Invasion and Metastasismentioning

confidence: 99%

The Effect of Intratumor Heterogeneity in Pancreatic Ductal Adenocarcinoma Progression and Treatment

Saleh,

Shihadeh,

Yousef

et al. 2024

Pancreas

View full text Add to dashboard Cite

Background and Objectives Pancreatic cancer is one of the most lethal malignancies. Even though many substantial improvements in the survival rates for other major cancer forms were made, pancreatic cancer survival rates have remained relatively unchanged since the 1960s. Even more, no standard classification system for pancreatic cancer is based on cellular biomarkers. This review will discuss and provide updates about the role of stem cells in the progression of PC, the genetic changes associated with it, and the promising biomarkers for diagnosis. Materials and Methods The search process used PubMed, Cochrane Library, and Scopus databases to identify the relevant and related articles. Articles had to be published in English to be considered. Results The increasing number of studies in recent years has revealed that the diversity of cancer-associated fibroblasts is far greater than previously acknowledged, which highlights the need for further research to better understand the various cancer-associated fibroblast subpopulations. Despite the huge diversity in pancreatic cancer, some common features can be noted to be shared among patients. Mutations involving CDKN2, P53, and K-RAS can be seen in a big number of patients, for example. Similarly, some patterns of genes and biomarkers expression and the level of their expression can help in predicting cancer behavior such as metastasis and drug resistance. The current trend in cancer research, especially with the advancement in technology, is to sequence everything in hopes of finding disease-related mutations. Conclusion Optimizing pancreatic cancer treatment requires clear classification, understanding CAF roles, and exploring stroma reshaping approaches.

show abstract

Section: Role Of Exosomes In Tumor Invasion and Metastasismentioning

confidence: 99%

The Effect of Intratumor Heterogeneity in Pancreatic Ductal Adenocarcinoma Progression and Treatment

Saleh,

Shihadeh,

Yousef

et al. 2024

Pancreas

View full text Add to dashboard Cite

show abstract

“…Notably, the numbers of cancer stem cells increase up to 36% of the total tumor cells in pancreatic cancer tissues, belonging to the highest among all of the malignant tumors examined [10] . More importantly, the numbers of cancer stem cells are closely associated with the poor prognosis in pancreatic cancer patients [10,11] . Therefore, pancreatic cancer stem cells are reasonable target for cancer therapy.…”

Section: Introductionmentioning

confidence: 98%

“…Pancreatic cancer stem cells, with the molecular markers CD44+, CD133+, CD24+, and ESA+, play pivotal roles in pancreatic cancer initiation, angiogenesis, metastasis, drug resistance, and tumor recurrence [7][8][9][10][11] . Notably, the numbers of cancer stem cells increase up to 36% of the total tumor cells in pancreatic cancer tissues, belonging to the highest among all of the malignant tumors examined [10] . More importantly, the numbers of cancer stem cells are closely associated with the poor prognosis in pancreatic cancer patients [10,11] .…”

Section: Introductionmentioning

confidence: 99%

Oncogenic CD44 is required for pancreatic cancer cell tumorigenesis and CD44 gene knockout is a new strategy for targeted pancreatic cancer therapy

Zhou,

Liu,

Meng

et al. 2024

Preprint

View full text Add to dashboard Cite

CD44 is a cancer stem cell marker and is aberrantly overexpressed in cancer stem/progenitor cells of malignant tumors. Overexpression of CD44 promotes carcinogenesis and is closely associated with poor prognosis in cancer patients, including pancreatic cancer. However, CD44-targeted drug against pancreatic cancer is unavailable in the clinical setting, and the effect of CD44 gene knockout on pancreatic cancer has not yet been reported in the literature. In this study, we investigated the effect of CD44 gene knockout on pancreatic cancer cell tumorigenesis. We found that CD44 genetic disruption notably inhibited pancreatic cancer cell tumorigenesis, migration, and invasion; increased intracellular DNA damage, sensitized pancreatic cancer cells to the anticancer drug cisplatin; and also suppressed tumor growth in xenograft mice. Mechanistically, CD44 genetic disruption suppressed expression of multiple oncogenic genes; particularly, the levels of oncogenic X-inactive specific transcription (Xist) were reduced for 35-fold through diminishing promoter activity, unraveling a novel oncogenic CD44-Xist axis in cancer cells. Additionally, CD44 genetic disruption inhibited the tumorigenic AKT and ERK signaling pathways, and concurrently activated the tumor-suppressive p38 and p53 signaling pathways. Our findings highlight the critical role of CD44 gene in pancreatic cancer and provide a new strategy for targeted pancreatic cancer therapy.

show abstract

“…Traditional treatment for pancreatic cancer involves surgical treatment combined with radiotherapy and chemotherapy (Yu et al, 2021). However, more than 80% patients are not eligible for surgical treatment owing to terminal cancer, and the cancer is prone to recurrence and metastasis even in patients who have undergone surgery (Kiemen et al, 2023; Zhao et al, 2023; Zhu, Liu, et al, 2023). Moreover, the damage to normal tissue caused by chemotherapy and radiotherapy remains a huge challenge.…”

Section: Introductionmentioning

confidence: 99%

Recent advances in sonodynamic therapy strategies for pancreatic cancer

Cheng,

Ming,

Cao

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Pancreatic cancer, a prevalent malignancy of the digestive system, has a poor 5‐year survival rate of around 10%. Although numerous minimally invasive alternative treatments, including photothermal therapy and photodynamic therapy, have shown effectiveness compared with traditional surgical procedures, radiotherapy, and chemotherapy. However, the application of these alternative treatments is constrained by their depth of penetration, making it challenging to treat pancreatic cancer situated deep within the tissue. Sonodynamic therapy (SDT) has emerged as a promising minimally invasive therapy method that is particularly potent against deep‐seated tumors such as pancreatic cancer. However, the unique characteristics of pancreatic cancer, including a dense surrounding matrix, high reductivity, and a hypoxic tumor microenvironment, impede the efficient application of SDT. Thus, to guide the evolution of SDT for pancreatic cancer therapy, this review addresses these challenges, examines current strategies for effective SDT enhancement for pancreatic cancer, and investigates potential future advances to boost clinical applicability.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Pancreatic cancer stemness: dynamic status in malignant progression

Cited by 9 publications

References 189 publications

The Effect of Intratumor Heterogeneity in Pancreatic Ductal Adenocarcinoma Progression and Treatment

The Effect of Intratumor Heterogeneity in Pancreatic Ductal Adenocarcinoma Progression and Treatment

Oncogenic CD44 is required for pancreatic cancer cell tumorigenesis and CD44 gene knockout is a new strategy for targeted pancreatic cancer therapy

Recent advances in sonodynamic therapy strategies for pancreatic cancer

Contact Info

Product

Resources

About